RESEARCH GRANTS
CURRENT RESEARCH GRANTS AND FUNDINGS RECEIVED
06/20-05/25
Title: Accelerating Precision Medicine Translation: Development of the First Evidence-based Clinical Exceptional Responder Gene-Drug Sensitivity Resource for Cancer
Source: Research Impact Fund
Role: PC
Amount: HKD 14,280,000
06/20-03/21
Postdoctoral Fellowship Scheme
Source: Faculty of Medicine, CUHK
Role: PI
Amount: HKD 250,000
02/20-01/21
Title: A Multi-omics Discovery of Clinically Relevant Immune Cell Surface Markers in Head and Neck Squamous Cell Carcinoma (HNSCC)
Source: Endowment Fund Research, United College, CUHK
Role: PI
Amount: HKD15,000
09/19-04/20
Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: InP/319/19
Source: ITF Internship Prog
Role: PI
Amount: HKD 156,940
03/19-02/23
Title: qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents (#1R01CA229836-01A1)
Source: NIH (NCI) USA
Role: Co-I
Amount: USD 497,880/y budgeted
06/19-05/24
Title: Patient-Derived Preclinical Models for Translational Cancer Research: A Hong Kong-Based Biotechnology Centre for Genomic Medicine (R4017-18)
Source: Research Impact Fund, HK
Role: Co-PI
Amount: HKD 9,800,000
06/18-05/21
Title: RAC1 Genomic alterations drive Head and neck cancer progression (# 14168517)
Source: GRF, HK
Role: PI
Amount: HKD 1,229,089
06/19-06/20
Postdoctoral Fellowship Scheme
Source: Faculty of Medicine, CUHK
Role: PI
Amount: HKD 205,560
09/19-09/22
Title: Overcoming chemoresistance in ovarian cancer by nanoscale co-delivery of imatinib and chemotherapeutic drugs “2017 HMRF Open Call Proposal” (#06173496)
Source: HMRF, HK
Role: Co-A
Amount: HKD 1,426,780
09/18–09/20
Title: RAPTOR: Investigating the prognostic significance and therapeutic value of RAPTOR-ness for Head and Neck Cancer (HNC) (#15160691)
Source: HMRF, HK
Role: PI
Amount: HKD 1,199,056
02/19-01/20
Title: A Multi-omics Approach for B cell Immune-Hotness Predictive of Patient Survival in Head and Neck Squamous Cell Carcinoma (HNSSC) (#CA11281)
Source: Endowment Fund Research, United College, CUHK
Role: PI
Amount: HKD 10,000
05/18-04/20
Title: Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Source: UICP (50%-50%) ITF/ Lee’s Pharmaceutical (Hong Kong) Limited
Role: PI
Amount: HKD 3,299,39 (HKD1.649.698 from ITF/ HKD1.649.698 from Lee’s)
02/19-04/20
Title: Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: PiH/234/18
Source: Post-doctoral Hub Programme / ITF
Role: PI
Amount: HKD 473,799.99
09/18-04/20
Title: Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: PiH/052/18
Source: Post-doctoral Hub Programme / ITF
Role: PI
Amount: HKD 626,355.75
09/18-04/20
Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: InP/241/18
Source: ITF Internship Prog
Role: PI
Amount: HKD 338,709.67
07/18-7/21
Novel Microneedle array loaded with Anti-PD-1-cisplatin-nanoparticles for Synergistic Cancer immune-chemotherapy (#17120718)
Source: GRF, HK
Role: Co-I
Amount: HKD 703,899
10/16-09/20
Affordable Multi-gene mutation-drug matching for recurrent ovarian cancer patients in Hong Kong (#4441953)
Source: Hong Kong Cancer Fund, HK
Role: PI
Amount: HKD 1,000,000
01/18-12/20
Incentive Scheme Award
Source: Faculty of Medicine, CUHK, HK
Role: PI
Amount: HKD 20,000
01/17-06/20
Title: ALK/PIK3CA Genetic coupling: Implications for progression and Personalized therapy in Head and Neck Cancer (#17121616)
Source: GRF, HK
Role: PI
Amount: HKD 840,664
​
05/16-04/19
Title : Start-up Fund, School of Biomedical Sciences (SBS), CUHK
Source: SBS, CUHK
Role:PI
Amount: HKD 1,500,000
PRIOR RESEARCH GRANTS RECEIVED
1999-2000
Title: University of Pittsburgh Graduate Training Program in breast cancer biology and therapy on “HER-2 ribozyme development”
Source: Department of Defense (DOD), USA
Role: Trainee
Amount: USD 1,000
12/99-8/00
Title: University of Pittsburgh Graduate Training Program in Breast Cancer Biology and Therapy On “HER-2 ribozyme development”
Source: Department of Defense(DOD) USA
Role: Trainee (100%)
Amount: USD 1,000
​
9/01-8/02
Title: Post-doctoral fellowship, Lung Cancer SPORE (Special Program of Research Excellence Grant) On “GRPR-mediated EGFR transactivation in NSCLC”
Source: NIH (NCI), USA
Role: Post-doctoral Fellow
Amount: USD 32,000
​
6/06-5/07
Title: Direct Grant for Research (2005/06) “Molecular Targeting of STAT3 for Nasopharyngeal Carcinoma (NPC)”(#2005.2.011)
Source: CUHK, HK
Role: PI
Amount: HKD 41,400
1/06-12/07
Title: Endowment Fund Research Grant “Exploring the potential of active c-Met signaling in Nasopharyngeal carcinoma (NPC)”
Source: CUHK, HK
Role: PI
Amount: HKD 10,000
6/07-5/08
Title: Direct Grant for Research (2006/07) “Targeted inhibition of c-Met induces downregulation of another key Receptor Tyrosine Kinase, EGFR: Implication for treatment of metastatic Nasopharyngeal Carcinoma (NPC)” (# 2006.1.027)
Source: CUHK, HK
Role: PI
Amount: HKD 78,250
4/07
Title: Academic Equipment Grant for BENCHMARK®LT Automated Slide Staining System
Source: CUHK, HK
Role: PI
Amount: HKD 598,000
1/07-12/08
Title: Lee Hysan Foundation Research Grant Endowment Fund Research Grant “Proteomics Changes Induced by DHMEQ,
a Novel NF-kB Inhibitor, in Nasopharyngeal Carcinoma (NPC)”
Source: CUHK, HK
Role: PI
Amount: HKD 30,000
​
5/08-4/09
Title: Direct Grant for Research (2007/08) “Biological Implication of Elevated Serum Hepatocyte Growth Factor (HGF) in the Progression of Nasopharyngeal Carcinoma (NPC)” (#2007.1.025) CUHK, HK
Role:PI
Amount: HKD 50,000
3/08-2/09
Title: TAIHO Research Funding “Preclinical antitumor activity of TAS-106 in NPC”
Source: TAHIO Pharmaceutical Co. Ltd., Japan
Role: PI
Amount: USD 20,000
​
1/09-12/09
Title: TAIHO Research Funding “Study on the involvement of TIGAR in the antitumor activity of TAS-106 in NPC”
Source: TAHIO Pharmaceutical Co. Ltd., Japan
Role: PI
Amount: USD 10,000
3/08-2-09
Title: Post-doctoral Fellowships Scheme for Intending Fellow (Application by PI)
Source: CUHK, HK
Role: PI
Amount: HKD 129,072
1/08-12/09
Title: Lee Hysan Foundation Research Grant Endowment Fund Research Grant “TIGAR in Chemoresistance of Nasopharyngeal cancer (NPC)”
Source: CUHK, HK
Role: PI
Amount: HKD 18,000
3/09-3/10
Title: Direct Grant for Research (2008/09) “Brain-derived neurotrophic factor signaling and the invasiveness of Hepatocarcinoma cells” (#2008.1.101)
Source: CUHK, HK
Role: Co-I
Amount: HKD 30,000
6/09-5/10
Title: Direct Grant for Research (2008/09) “A Novel Signaling Axis of STAT3/c-Met Regulation in Non-Small Cell Lung Cancer (NSCLC): A Direct Link between Two Important Players of Metastasis” (# 2008.1.025)
Source: CUHK, HK
Role: PI
Amount: HKD 62,000
​
3/10-3/11
Title: Direct Grant for Research (2009/10) “A Novel Signaling Axis of TIGAR Induction by EGFR in Non-small Cell Lung Cancer (NSCLC)” (# 2009.1.012)
Source: CUHK, HK
Role: PI
Amount: HKD 35,000
​
3/10-3/11
Title: Direct Grant for Research (2009/10) “The role of mTOR inhibition with nab-rapamycin in enhancing chemosensitivity of
microtubule-stabilizing agent Abraxane in HCC” (# 2009.1.015)
Source: CUHK, HK
Role: Co-I
Amount: HKD 100,000
6/10-5/11
Title: Research Grant from Novartis (MA, USA) “PI3-K targeting in Nasopharyngeal cancer”
Source: Novartis,USA
Role: Co-I
Amount: USD 30,000
1/07-12/10
Title: Competitive Earmarked Research Grant “Intrinsic Mechanism of c-Met induction as a point for therapeutic intervention for aggressive Nasopharyngeal Carcinoma (NPC)” (#471607)
Source: Research Grant Councils, HK Government, HK
Role: PI
Amount: HKD 1,049,224
10/08-9/11
Title: Competitive Earmarked Research Grant “The role of STAT activation in regulating persistence of EBV infection in premalignant nasopharyngeal epithelial cell model” (#776608)
Source: Research Grant Councils, HK Government, HK
Role: Co-I
Amount: HKD 1,110,847
​
7/10-4/11
Title: Competitive General Research Fund “Oncogenic Regulation of TIGAR by STAT3: A Mechanistic Study” (# 471810)
Source: Research Grant Councils, HK Government, HK
Role: PI
Amount: HKD 1,150,000
​
1/10-2/11
Title: Preclinical evaluation of MK in NPC
Source: Merck & Co., Inc (MSD)
Role: Co-I
Amount: USD 10,000
​
2/08-12/11
Merit Award for GRF Project “The role of STAT activation in regulating persistence of EBV infection in premalignant
nasopharyngeal epithelial cell model” (HKU776608M)
Source: University of Hong Kong, HK
Role: Co-I
Amount: HKD 50,000
8/06-8/12
Title: Li Ka Shing Institute for Health Sciences “Asian Cancer Studies-Cancer Drug Testing”
Source: CUHK, HK
Role: Co-PI
Amount: HKD 3,600,000
8/11-7/12
Title: Head and Neck SPORE Developmental Research Award: “A Functional Genomic Platform to Identify Driver Mutations and
Effective Targeted Therapy for Head and Cancers”
Source: NIH (NCI), USA
Role: PI
Amount: USD 75,750
9/11-8/12
Title: Genomic Analysis of Oncovirus-Associated Head and Neck Cancers in US and Chinese (US NIH-China NSFC)
Populations
Source: NIH, USA
Role: Co-I
Amount: USD 100,000
12/10-12/12
Title: Clinical Trial Grant from Pfizer “RTK Targeting in Nasopharyngeal cancer patients (Clinical Trial)”
Source: Pfizer
Role: Co-I
Amount: USD 86,064.52
7/10-6/13
Title: Competitive General Research Fund “Oncogenic Regulation of TIGAR by
STAT3: A Mechanistic Study” (# 471810)
Research Grant Councils, HK Government, HK
Role: Co-I (5/11-6/13) PI (7/10-4/11)
Amount: HKD 1,150,00
9/10-6/13
Title: Research Incentive Scheme (award)
Source: CUHK, HK
Role: PI
Amount: HKD 20,000
7/11-6/13
Title: Rare Head and Neck Malignancies for Therapeutic Target Identification for Individualized Therapy Pittsburgh Foundation
Source: Pittsburgh Foundation (The Patricia L. Knebel Fund)
Role: PI
Amount: USD 10,000
​
05/12-11/13
Title: Anti-tumor mechanisms of PIK3CA inhibition (by BYL719) in preclinical HNSCC models
Source: Novartis, USA
Role: PI
Amount: USD 55,597
​
06/12-12/13
Title: Anti-tumor mechanisms of PIK3CA inhibition (by BKM120) in preclinical HNSCC models
Source: Novartis, USA
Role: PI
Amount: USD 55,597
​
09/12-10/13
Title: Testing Cancer Drug Combinations in 10 SCCHN Cell Lines (SPORE in Head Neck Cancer Developmental Research Program)
Source: NIH (NCI), USA
Role: Co-PI
Amount: USD 22,078
2/11-6/15
Title: Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer Career Development Program
Source: NIH (NCI), USA
Role: Co-I
Amount: USD 59,328
06/15-05/16
Title: Micro-PET Imaging for direct assessment of Drug-induced cell death in NPC models
Source: NPC-AoE Project, HK
Role: Co-I
Amount: HKD 150,000
07/15-7/16
Title: A pilot study to identify breast Cancer cell models for functional Genomics and Proteomics
Source: Strategic Theme Research, HKU
Role: PI
Amount: HKD 100,000
​
02/15-02/17
Title: A Precision therapeutic tool for head & Neck cancer
Source: Applied Research, HKU
Role: PI
Amount: HKD 100,000
07/14-06/16
Title: ALK inhibitors for Head & Neck Seed Funding for Cancer therapy
Source: Basic Research, HKU
Role: PI
Amount: HKD120,000
​
07/14-06/16
ALK inhibitors for Head & Neck Matching for Seed Cancer therapy
Source: Funding for Basic Research, HKU
Role: PI
Amount: HKD120,000
​